Simulated Cell News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Accenture Ventures makes a strategic investment in Turbine, a company pioneering the use of predictive cell simulations for drug development.

— Companies will co-develop inhibitors of a dark kinase target (NEK1) identified for cancer dependency by Turbine’s Simulated Cell™ platform — LONDON & BUDAPEST, Hungary & NEW YORK--(BUSINESS WIRE)--Turbine, a company that is building the world’s first predictive simulation...

-- Enhanced financial resources and expertise will further Turbine's interpretable simulation research and maximize the potential of its Simulated Cell™ platform -- Turbine's proprietary approach pairs

Turbine’s AI-powered Cancer Cell Simulations Will Be Used to Identify Novel Disease Positioning Strategies in Cancer Research UK’s Latest Biotech Partnership LONDON & BUDAPEST, Hungary – Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder...

Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cancer research, Cancer Research UK, is partnering with Turbine,* a tech-enabled biotech leveraging

Turbine – a London-based company with a cell simulation platform that can predict the effectiveness of cancer treatments – has completed a €20m Series A financing round. Mercia and MSD Global Health Innovation (GHI) Fund (MSD is the trade name of Merck & Co., Inc., Rahway NJ, USA) co-led the financing, joined by ...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

€20m financing will focus on treatment pathways, new partnerships and team expansion - News - PharmaTimes

Merck & Co's strategic investment fund was revealed as a co-lead investor.